Protective immunity and vaccination against cutaneous leishmaniasis

Frontiers in Immunology

Volumn 3, Issue MAY, 2012, Pages

  Okwor, Ifeoma ^a   Mou, Zhirong ^a   Liu, Dong ^a   Uzonna, Jude ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Adaptive immunity; Cutaneous leishmaniasis; Infection induced resistance; Innate immunity; Vaccination; Vaccine

Indexed keywords

EID: 84874066814     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00128     Document Type: Review

References (172)

1. Aebischer, T., Moody, S. F., and Handman, E. (1993). Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect. Immun. 61, 220-226.
2. Afonso, L. C., Scharton, T. M., Vieira, L. Q., Wysocka, M., Trinchieri, G., and Scott, P. (1994). The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263, 235-237.
3. Aga, E., Katschinski, D. M., van Zandbergen, G., Laufs, H., Hansen, B., Müller, K., Solbach, W., and Laskay, T. (2002). Inhibition of the spontaneous apoptosis of neutrophil granulocytes by the intracellular parasite Leishmania major. J. Immunol. 169, 898-905.
4. Akilov, O. E., Ustyugova, I. V., Zhi, L., Hasan, T., and Wu, M. X. (2009). Enhanced susceptibility to Leishmania infection in resistant mice in the absence of immediate early response gene X-1. J. Immunol. 183, 7994-8003.
5. Alarcon, J. B., Waine, G. W., and McManus, D. P. (1999). DNA vaccines: technology and application as anti-parasite and anti-microbial agents. Adv. Parasitol. 42, 343-410.
6. Alexander, J., Brombacher, F., McGachy, H. A., McKenzie, A. N., Walker, W., and Carter, K. C. (2002). An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection. Eur. J. Immunol. 32, 2923-2933.
7. Alexander, J., Coombs, G. H., and Mottram, J. C. (1998). Leishmania mexicana cysteine proteinasedeficient mutants have attenuated virulence for mice and potentiate a Th1 response. J. Immunol. 161, 6794-6801.
8. Amaral,V. F., Teva,A., Oliveira-Neto, M. P., Silva, A. J., Pereira, M. S., Cupolillo, E., Porrozzi, R., Coutinho, S. G., Pirmez, C., Beverley, S. M., and Grimaldi G, J. r. (2002). Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease. Mem. Inst. Oswaldo Cruz 97, 1041-1048.
9. Anderson, C. F., Mendez, S., and Sacks, D. L. (2005). Nonhealing infection despite Th1 polarization produced byastrainofLeishmania major in C57BL/6 mice. J. Immunol. 174, 2934-2941.
10. Anderson, C. F., Oukka, M., Kuchroo, V. J., and Sacks, D. (2007). CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10mediated immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 204, 285-297.
11. Anderson,C. F.,Stumhofer,J. S.,Hunter, C. A., and Sacks, D. (2009). IL27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection. J. Immunol. 183, 4619-4627.
12. Armijos, R. X., Weigel, M. M., Calvopina, M., Hidalgo, A., Cevallos, W., and Correa, J. (2004). Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 22, 1320-1326.
13. Bailey, M. S. (2011). Cutaneous leishmaniasis in British troops following jungle training in Belize. Travel Med. Infect Dis. 9, 253-254.
14. Belkaid, Y., Piccirillo, C. A., Mendez, S., Shevach, E. M., and Sacks, D. L. (2002). CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420, 502-507.
15. Belosevic, M., Finbloom, D. S., Van Der Meide, P. H., Slayter, M. V., and Nacy, C. A. (1989). Administration of monoclonal anti-IFNgamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J. Immunol. 143, 266-274.
16. Birnbaum, R., and Craft, N. (2011). Innate immunity and Leishmania vaccination strategies. Dermatol. Clin. 29, 89-102.
17. Boaventura, V. S., Santos, C. S., Cardoso, C. R., de Andrade, J., Dos Santos, W. L., Clarêncio, J., Silva, J. S., Borges, V. M., Barral-Netto, M., Brodskyn, C. I., and Barral, A. (2010). Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. Eur. J. Immunol. 40, 2830-2836.
18. Bourreau, E., Ronet, C., Darcissac, E., Lise, M. C., Sainte Marie, D., Clity, E., Tacchini-Cottier, F., Couppie, P., and Launois, P. (2009). Intralesional regulatory T-cell suppressive function during human acute and chronic cutaneous leishmaniasis due to Leishmania guyanensis. Infect. Immun. 77, 1465-1474.
19. Breton, M., Tremblay, M. J., Ouellette, M., and Papadopoulou, B. (2005). Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect. Immun. 73, 6372-6382.
20. Brodskyn, C., Beverley, S. M., and Titus, R. G. (2000). Virulent or avirulent (dhfr-ts-) Leishmania major elicit predominantly a type-1 cytokine response by human cells in vitro. Clin. Exp. Immunol. 119, 299-304.
21. Brombacher, F. (2000). The role of interleukin-13 in infectious diseases and allergy. Bioessays 22, 646-656.
22. Brombacher, F. (ed.). (2003). Interleukin-13. Georgetown, TX: Landes Bioscience.
23. Campanelli, A. P., Roselino, A. M., Cavassani, K. A., Pereira, M. S., Mortara, R. A., Brodskyn, C. I., Goncalves, H. S., Belkaid, Y., BarralNetto, M., Barral, A., and Silva, J. S. (2006). CD4+CD25+ T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. J. Infect. Dis. 193, 1313-1322.
24. Chang, S. H., Reynolds, J. M., Pappu, B. P., Chen, G., Martinez, G. J., and Dong, C. (2011). Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 35, 611-621.
25. Chappuis, J., Simoens, C., Smets, D., Duttmann,R.,and Mendes da Costa, P. (2007). Spontaneous rupture of the spleen in relation to a nonHodgkin lymphoma. Acta Chir. Belg. 107:446-448.
26. Chatelain, R., Mauze, S., and Coffman, R. L. (1999). Experimental Leishmania major infection in mice: role of IL-10. Parasite Immunol. 21, 211-218.
27. Coler, R. N., Goto, Y., Bogatzki, L., Raman, V., and Reed, S. G. (2007). Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect. Immun. 75, 4648-4654.
28. Daneshvar, H., Burchmore, R., Hagan, P., and Phillips, R. S. (2009). Leishmania major H-line attenuated under pressure of gentamicin, induces a Th1 response which protects susceptible BALB/c mice against infection with virulent Leishmania major. Parasitology 136, 1243-1250.
29. Davoudi, N., Tate, C. A., Warburton, C., Murray, A., Mahboudi, F., and McMaster, W. R. (2005). Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials. Vaccine 23, 1170-1177.
30. Desjeux, P. (1996). Leishmaniasis. Public health aspects and control. Clin. Dermatol. 14, 417-423.
31. Di Santo, E., Meazza, C., Sironi, M., Fruscella, P., Mantovani, A., Sipe, J. D., and Ghezzi, P. (1997). IL-13 inhibits TNF production but potentiates that of IL-6 in vivo and ex vivo in mice. J. Immunol. 159, 379-382.
32. Doroud, D., Zahedifard, F., Vatanara, A., Taslimi, Y., Vahabpour, R., Torkashvand, F., Vaziri, B., Rouholamini Najafabadi, A., and Rafati, S. (2011a). C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice. PLoS Negl. Trop. Dis. 5,e1236. doi:10.1371/journal.pntd.0001236
33. Doroud, D., Zahedifard, F., Vatanara, A., Najafabadi, A. R., Taslimi, Y., Vahabpour, R., Torkashvand, F., Vaziri, B., and Rafati, S. (2011b). Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J. Control. Release 153, 154-162.
34. Doyle, A. G., Herbein, G., Montaner, L. J., Minty, A. J., Caput, D., Ferrara, P., and Gordon, S. (1994). Interleukin13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-gamma. Eur. J. Immunol. 24, 1441-1445.
35. Elhay, M., Kelleher, M., Bacic, A., McConville, M. J., Tolson, D. L., Pearson, T. W., and Handman, E. (1990). Lipophosphoglycan expression and virulence in ricinresistant variants of Leishmania major. Mol. Biochem. Parasitol. 40, 255-267.
36. Farrell, J. P., and Kirkpatrick, C. E. (1987). Experimental cutaneous leishmaniasis. II. A possible role for prostaglandins in exacerbation of disease in Leishmania majorinfected BALB/c mice. J. Immunol. 138, 902-907.
37. Fiorentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M., Moore, K. W., and O'Garra, A. (1991). IL-10 acts on the antigenpresenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146, 3444-3451.
38. Fragaki, K., Suffia, I., Ferrua, B., Rousseau, D., Le Fichoux, Y., and Kubar, J. (2001). Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters. Vaccine 19, 1701-1709.
39. Gicheru, M. M., Olobo, J. O., Anjili, C. O., Orago, A. S., Modabber, F., and Scott, P. (2001). Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect. Immun. 69, 245-251.
40. Goto, Y., Bhatia, A., Raman, V. S., Liang, H., Mohamath, R., Picone, A. F., Vidal, S. E., Vedvick, T. S., Howard, R. F., and Reed, S. G. (2011). KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis. Clin. Vaccine Immunol. 18, 1118-1124.
41. Gradoni, L., Foglia Manzillo,V., Pagano, A., Piantedosi, D., De Luna, R., Gramiccia, M., Scalone, A., Di Muccio, T., and Oliva, G. (2005). Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 23, 5245-5251.
42. Greenblatt, C. L. (1980). The present and future of vaccination for cutaneous leishmaniasis. Prog. Clin. Biol. Res. 47, 259-285.
43. Gurunathan, S., Prussin, C., Sacks, D. L., and Seder, R. A. (1998). Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4, 1409-1415.
44. Gurunathan, S., Sacks, D. L., Brown, D. R., Reiner, S. L., Charest, H., Glaichenhaus, N., and Seder, R. A. (1997). Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186, 1137-1147.
45. Gurunathan, S., Wu, C. Y., Freidag, B. L., and Seder, R. A. (2000a). DNA vaccines: a key for inducing longterm cellular immunity. Curr. Opin. Immunol. 12, 442-447.
46. Gurunathan, S., Klinman, D. M., and Seder, R. A. (2000b). DNA vaccines: immunology, application, and optimization*. Annu. Rev. Immunol. 18, 927-974.
47. Handman, E. (2001). Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14, 229-243.
48. Handman,E.,Button,L. L.,and McMaster, R. W. (1990). Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice. Exp. Parasitol. 70, 427-435.
49. Heinzel, F. P., Rerko, R. M., Ahmed, F., and Pearlman, E. (1995). Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J. Immunol. 155, 730-739.
50. Heinzel, F. P., Sadick, M. D., Holaday, B. J., Coffman, R. L., and Locksley, R. M. (1989). Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169, 59-72.
51. Heinzel, F. P., Schoenhaut, D. S., Rerko, R. M., Rosser, L. E., and Gately, M. K. (1993). Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 177, 1505-1509.
52. Himmelrich, H., Launois, P., Maillard, I., Biedermann, T., Tacchini-Cottier, F., Locksley, R. M., Röcken, M., and Louis, J. A. (2000). In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J. Immunol. 164, 4819-4825.
53. Himmelrich, H., Parra-Lopez, C., Tacchini-Cottier, F., Louis, J. A., and Launois, P. (1998). The IL-4 rapidly produced in BALB/c mice after infection with Leishmania major down-regulates IL-12 receptor beta 2-chain expression on CD4+ T cells resulting in a state of unresponsiveness to IL-12. J. Immunol. 161, 6156-6163.
54. Holaday, B. J., Sadick, M. D., Wang, Z. E., Reiner, S. L., Heinzel, F. P., Parslow, T. G., and Locksley, R. M. (1991). Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1and Th2-like cell lines. J. Immunol. 147, 1653-1658.
55. Huber, M., Timms, E., Mak, T. W., Röllinghoff, M., and Lohoff, M. (1998). Effective and long-lasting immunity against the parasite Leishmania major in CD8-deficient mice. Infect. Immun. 66, 3968-3970.
56. Jaafari, M. R., Badiee, A., Khamesipour, A., Samiei, A., Soroush, D., Kheiri, M. T., Barkhordari, F., McMaster, W. R., and Mahboudi, F. (2007). The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 25, 6107-6117.
57. John, B., and Hunter, C. A. (2008). Immunology. Neutrophil soldiers or Trojan horses Science 321, 917-918. Jones,D. E.,Ackermann,M. R.,Wille,U., Hunter, C. A., and Scott, P. (2002). Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect. Immun. 70, 2151-2158.
58. Kane, M. M., and Mosser, D. M. (2000). Leishmania parasites and their ploys to disrupt macrophage activation. Curr. Opin. Hematol. 7, 26-31.
59. Kedzierski, L., Curtis, J. M., Doherty, P. C., Handman, E., and Kedzierska, K. (2008). Decreased IL-10 and IL-13 production and increased CD44hi T cell recruitment contribute to Leishmania major immunity induced by non-persistent parasites. Eur. J. Immunol. 38, 3090-3100.
60. Kedzierski, L., Zhu, Y., and Handman,E. (2006). Leishmania vaccines: progress and problems. Parasitology 133(Suppl.), S87-S112.
61. Khalil, E. A., El Hassan, A. M., Zijlstra, E. E., Mukhtar, M. M., Ghalib, H. W., Musa, B., Ibrahim, M. E., Kamil, A. A., Elsheikh, M., Babiker, A., and Modabber, F. (2000). Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCGcontrolled trial in Sudan. Lancet 356, 1565-1569.
62. Khamesipour, A., Dowlati, Y., Asilian, A., Hashemi-Fesharki, R., Javadi, A., Noazin, S., and Modabber, F. (2005). Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23, 3642-3648.
63. Korbel, D. S., Finney, O. C., and Riley, E. M. (2004). Natural killer cells and innate immunity to protozoan pathogens. Int. J. Parasitol. 34, 1517-1528.
64. Laabs, E. M., Wu, W., and Mendez, S. (2009). Vaccination with live Leishmania major and CpG DNA promotes interleukin-2 production by dermal dendritic cells and NK cell activation. Clin. Vaccine Immunol. 16, 1601-1606.
65. Lages, C. S., Suffia, I., Velilla, P. A., Huang, B., Warshaw, G., Hildeman, D. A., Belkaid, Y., and Chougnet, C. (2008). Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J. Immunol. 181, 1835-1848.
66. Laurenti, M. D., Gidlund, M., Ura, D. M., Sinhorini, I. L., Corbett, C. E., and Goto, H. (1999). The role of natural killer cells in the early period of infection in murine cutaneous leishmaniasis. Braz. J. Med. Biol. Res. 32, 323-325.
67. Leon, B., Lopez-Bravo, M., and Ardavin, C. (2007). Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 26, 519-531.
68. Lerner, E. A., and Shoemaker, C. B. (1992). Maxadilan. Cloning and functional expression of the gene encoding this potent vasodilator peptide. J. Biol. Chem. 267, 1062-1066.
69. Liese, J., Schleicher, U., and Bogdan, C. (2008). The innate immune response against Leishmania parasites. Immunobiology 213, 377-387. Liew, F. Y., Li, Y., and Millott, S. (1990a). Tumour necrosis factor (TNF-alpha) in leishmaniasis. II. TNF-alpha-induced macrophage leishmanicidal activity is mediated by nitric oxide from L-arginine. Immunology 71, 556-559.
70. Liew, F. Y., Parkinson, C., Millott, S., Severn, A., and Carrier, M. (1990b). Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology 69, 570-573.
71. Lira, R., Sundar, S., Makharia, A., Kenney, R., Gam, A., Saraiva, E., and Sacks, D. (1999). Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180, 564-567.
72. Liu, D., and Uzonna, J. E. (2010). The p110 delta isoform of phosphatidylinositol 3-kinase controls the quality of secondary anti-Leishmania immunity by regulating expansion and effector function of memory T cell subsets. J. Immunol. 184, 3098-3105.
73. Liu, D., Zhang, T., Marshall, A. J., Okkenhaug, K., Vanhaesebroeck, B., and Uzonna, J. E. (2009). The p110delta isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells. J. Immunol. 183, 1921-1933.
74. Llanos-Cuentas, A., Calderón, W., Cruz, M., Ashman, J. A., Alves, F. P., Coler, R. N., Bogatzki, L. Y., Bertholet, S., Laughlin, E. M., Kahn, S. J., Beckmann, A. M., Cowgill, K. D., Reed, S. G., and Piazza, F. M. (2010).A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 28, 7427-7435.
75. Locksley, R. M., Wakil, A. E., Corry, D. B., Pingel, S., Bix, M., and Fowell, D. J. (1995). The development of effector T cell subsets in murine Leishmania major infection. Ciba Found. Symp. 195, 110-117; discussion 117-122.
76. Lopez Kostka, S., Dinges, S., Griewank, K., Iwakura, Y., Udey, M. C., and von Stebut, E. (2009). IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J. Immunol. 182, 3039-3046.
77. Louis, J. A., Conceiçao-Silva, F., Himmelrich, H., Tacchini-Cottier, F., and Launois, P. (1998a). Anti-leishmania effector functions of CD4+ Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice. Adv. Exp. Med. Biol. 452, 53-60.
78. Louis, J., Himmelrich, H., Parra-Lopez, C., Tacchini-Cottier, F., and Launois, P. (1998b). Regulation of protective immunity against Leishmania major in mice. Curr. Opin. Immunol. 10, 459-464.
79. Makala, L. H., Baban, B., Lemos, H., El-Awady, A. R., Chandler, P. R., Hou, D. Y., Munn, D. H., and Mellor, A. L. (2011). Leishmania major attenuates host immunity by stimulating local indoleamine 2,3dioxygenase expression. J. Infect. Dis. 203, 715-725.
80. Masih, S., Arora, S. K., and Vasishta, R. K. (2011). Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis. Exp. Parasitol. 129, 55-64.
81. Matthews, D. J., Emson, C. L., McKenzie, G. J., Jolin, H. E., Blackwell, J. M., and McKenzie, A. N. (2000). IL-13 is a susceptibility factor for Leishmania major infection. J. Immunol. 164, 1458-1462.
82. Mazumder, S., Maji, M., Das, A., and Ali, N. (2011). Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice. PLoS ONE 6, e14644. doi:10.1371/journal.pone.0014644
83. Melby, P. C., Yang, J., Zhao, W., Perez, L. E., and Cheng, J. (2001). Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69, 4719-4725.
84. Mendez, S., Reckling, S. K., Piccirillo, C. A., Sacks, D., and Belkaid, Y. (2004). Role for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J. Exp. Med. 200, 201-210.
85. Mendez, S., Tabbara, K., Belkaid, Y., Bertholet, S., Verthelyi, D., Klinman, D., Seder, R. A., and Sacks, D. L. (2003). Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability. Infect. Immun. 71, 5121-5129.
86. Milano, S., Arcoleo, F., Dieli, M., D'Agostino, R., De Nucci, G., D'Agostino, P., and Cillari, E. (1996). Ex vivo evidence for PGE2 and LTB4 involvement in cutaneous leishmaniasis: relation with infection status and cytokine production. Parasitology 112(Pt 1), 13-19.
87. Mizbani, A., Taheri, T., Zahedifard, F., Taslimi, Y., Azizi, H., Azadmanesh, K., Papadopoulou, B., and Rafati, S. (2009). Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 28, 53-62.
88. Mohrs, M., Ledermann, B., Köhler, G., Dorfmüller, A., Gessner, A., and Brombacher, F. (1999). Differences between IL-4and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J. Immunol. 162, 7302-7308.
89. Momeni, A. Z., and Aminjavaheri, M. (1995). Treatment of recurrent cutaneous Leishmaniasis. Int. J. Dermatol. 34, 129-133.
90. Momeni, A. Z., Jalayer, T., Emamjomeh, M., Khamesipour, A., Zicker, F., Ghassemi, R. L., Dowlati, Y., Sharifi, I., Aminjavaheri, M., Shafiei, A., Alimohammadian, M. H., HashemiFesharki, R., Nasseri, K., Godal, T., Smith, P. G., and Modabber, F. (1999). A randomised, doubleblind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17, 466-472.
91. Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., and Coffman, R. L. (1986). Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348-2357.
92. Mosmann, T. R., and Moore, K. W. (1991). The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol. Today 12, A49-A53.
93. Mou, Z., Jia, P., Kuriakose, S., Khadem, F., and Uzonna, J. E. (2010). Interleukin-17-mediated control of parasitemia in experimental Trypanosoma congolense infection in mice. Infect. Immun. 78, 5271-5279.
94. Mougneau, E., Altare, F., Wakil, A. E., Zheng, S., Coppola, T., Wang, Z. E., Waldmann, R., Locksley, R. M., and Glaichenhaus, N. (1995). Expression cloning of a protective Leishmania antigen. Science 268, 563-566.
95. Mougneau, E., Bihl, F., and Glaichenhaus, N. (2011). Cell biology and immunology of Leishmania. Immunol. Rev. 240, 286-296.
96. Mueller, T. D., Zhang, J. L., Sebald, W., and Duschl, A. (2002). Structure, binding, and antagonists in the IL-4/IL-13 receptor system. Biochim. Biophys. Acta 1592, 237-250.
97. Muyombwe, A., Olivier, M., Ouellette, M., and Papadopoulou, B. (1997). Selective killing of Leishmania amastigotes expressing a thymidine kinase suicide gene. Exp. Parasitol. 85, 35-42.
98. Nascimento, E., Fernandes, D. F., Vieira, E. P., Campos-Neto, A., Ashman, J. A., Alves, F. P., Coler, R. N., Bogatzki, L. Y., Kahn, S. J., Beckmann, A. M., Pine, S. O., Cowgill, K. D., Reed, S. G., and Piazza, F. M. (2010). A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 28, 6581-6587.
99. Nashleanas, M., and Scott, P. (2000). Activated T cells induce macrophages to produce NO and control Leishmania major in the absence of tumor necrosis factor receptor p55. Infect. Immun. 68, 1428-1434.
100. Noben-Trauth, N., and Kropf, P. (1996). Muller I. Susceptibility to Leishmania major infection in interleukin-4deficient mice. Science 271, 987-990.
101. Noben-Trauth, N., Lira, R., Nagase, H., Paul, W. E., and Sacks, D. L. (2003). The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J. Immunol. 170, 5152-5158.
102. Noben-Trauth, N., Paul, W. E., and Sacks, D. L. (1999). IL-4and IL4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J. Immunol. 162, 6132-6140.
103. Novais, F. O., Santiago, R. C., Báfica, A., Khouri, R., Afonso, L., Borges, V. M., Brodskyn, C., Barral-Netto, M., Barral, A., and de Oliveira, C. I. (2009). Neutrophils and macrophages cooperate in host resistance against Leishmania braziliensis infection. J. Immunol. 183, 8088-8098.
104. Nylen, S., Maasho, K., Söderstrom, K., Ilg, T., and Akuffo, H. (2003). Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clin. Exp. Immunol. 131, 457-467.
105. Okwor, I., Kuriakose, S., and Uzonna, J. (2010). Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge. Vaccine 28, 5451-5457.
106. Okwor, I., Liu, D., Beverley, S. M., and Uzonna, J. E. (2009). Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process. Proc. Natl. Acad. Sci. U.S.A. 106, 13951-13956.
107. Okwor, I., and Uzonna, J. (2008). Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. Immunol. Res. 41, 123-136.
108. Okwor, I., and Uzonna, J. (2009). Vaccines and vaccination strategies against human cutaneous leishmaniasis. Hum. Vaccin. 5, 291-301.
109. Olobo, J. O., Anjili, C. O., Gicheru, M. M., Mbati, P. A., Kariuki, T. M., Githure, J. I., Koech, D. K., and McMaster, W. R. (1995). Vaccination of vervet monkeys against cutaneous Leishmaniosis using recombinant Leishmania "major surface glycoprotein" (gp63). Vet. Parasitol. 60, 199-212.
110. Padigel, U. M., Alexander, J., and Farrell, J. P. (2003). The role of interleukin10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J. Immunol. 171, 3705-3710.
111. Palatnik-de-Sousa, C. B. (2008). Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 26, 1709-1724.
112. Paludan, S. R., Lovmand, J., EllermannEriksen, S., and Mogensen, S. C. (1997). Effect of IL-4 and IL13 on IFN-gamma-induced production of nitric oxide in mouse macrophages infected with herpes simplex virus type 2. FEBS Lett. 414, 61-64.
113. Park, A. Y., Hondowicz, B. D., and Scott, P. (2000). IL-12 is required to maintain a Th1 response during Leishmania major infection. J. Immunol. 165, 896-902.
114. Peters, N. C., Egen, J. G., Secundino, N., Debrabant, A., Kimblin, N., Kamhawi, S., Lawyer, P., Fay, M. P., Germain,R. N.,and Sacks,D. (2008). In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 321, 970-974.
115. Pitta, M. G., Romano, A., Cabantous, S., Henri, S., Hammad, A., Kouriba, B., Argiro, L., el Kheir, M., Bucheton, B., Mary, C., El-Safi, S. H., and Dessein, A. (2009). IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J. Clin. Invest. 119, 2379-2387.
116. Racoosin, E. L., and Beverley, S. M. (1997). Leishmania major:promastigotes induce expression of a subset of chemokine genes in murine macrophages. Exp. Parasitol. 85, 283-295.
117. Rafati, S., Nakhaee, A., Taheri, T., Ghashghaii, A., Salmanian, A. H., Jimenez, M., Mohebali, M., Masina, S., and Fasel, N. (2003). Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis. Exp. Parasitol. 103, 143-151.
118. Reiner, S. L., and Locksley, R. M. (1995). The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13, 151-177.
119. Reinhard, K., Huber, M., Wostl, C., Hellhund, A., Toboldt, A., Abass, E., Casper, B., Joeris, T., Herr, C., Bals, R., Steinhoff, U., Lohoff, M., and Visekruna, A. (2011). cRel promotes type 1 and type 17 immune responses during Leishmania major infection. Eur. J. Immunol. 41, 1388-1398.
120. Reithinger, R., Dujardin, J. C., Louzir, H., Pirmez, C., Alexander, B., and Brooker, S. (2007). Cutaneous leishmaniasis. Lancet Infect. Dis. 7, 581-596.
121. Restifo, N. P., Ying, H., Hwang, L., and Leitner, W. W. (2000). The promise of nucleic acid vaccines. Gene Ther. 7, 89-92.
122. Rey, A., Quartulli, F., Escoubet, L., Sozzani, P., Caput, D., Ferrara, P., and Pipy, B. (1999). IL-13 induces serine phosphorylation of cPLA2 in mouse peritoneal macrophages leading to arachidonic acid and PGE2 production and blocks the zymosan-induced serine phosphorylation of cPLA2 and eicosanoid production. Biochim. Biophys. Acta 1440, 183-193.
123. Rezvan, H., Rees, R., and Ali, S. (2011). Leishmania mexicana Gp63 cDNA using gene gun induced higher immunity to L. mexicana infection compared to soluble Leishmania antigen in BALB/C. Iran. J. Parasitol. 6, 60-75.
124. Rivier, D., Shah, R., Bovay, P., and Mauel, J. (1993). Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunol. 15, 75-84.
125. Rutschman, R., Lang, R., Hesse, M., Ihle, J. N., Wynn, T. A., and Murray, P. J. (2001). Cutting edge: Stat6dependent substrate depletion regulates nitric oxide production. J. Immunol. 166, 2173-2177.
126. Salay, G., Dorta, M. L., Santos, N. M., Mortara, R. A., Brodskyn, C., Oliveira, C. I., Barbiéri, C. L., and Rodrigues, M. M. (2007). Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World. Clin. Vaccine Immunol. 14, 1173-1181.
127. Saldarriaga, O. A., Travi, B. L., Park, W., Perez, L. E., and Melby, P. C. (2006). Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. Vaccine 24, 1928-1940.
128. Saravia, N. G., Escorcia, B., Osorio, Y., Valderrama, L., Brooks, D., Arteaga, L., Coombs, G., Mottram, J., and Travi, B. L. (2006). Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models. Vaccine 24, 4247-4259.
129. Scharton, T. M., and Scott, P. (1993). Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J. Exp. Med. 178, 567-577.
130. Scott, P. (1989). The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis. Exp. Parasitol. 68, 369-372.
131. Scott, P. (1991). IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J. Immunol. 147, 3149-3155.
132. Scott, P. (1997). Trinchieri G. IL-12 as an adjuvant for cell-mediated immunity. Semin. Immunol. 9, 285-291.
133. Scott, P., Natovitz, P., Coffman, R. L., Pearce, E., and Sher, A. (1988). Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J. Exp. Med. 168, 1675-1684.
134. Scott, P., Pearce, E., Cheever, A. W., Coffman, R. L., and Sher, A. (1989). Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease. Immunol. Rev. 112, 161-182.
135. Singh, S. P., Reddy, D. C., Rai, M., and Sundar, S. (2006). Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop. Med. Int. Health 11, 899-905.
136. Singh, V. P., Ranjan, A., Topno, R. K., Verma, R. B., Siddique, N. A., Ravidas, V. N., Kumar, N., Pandey, K., and Das, P. (2010). Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India. Am. J. Trop. Med. Hyg. 82, 9-11.
137. Sjolander, A., Baldwin, T. M., Curtis, J. M., and Handman, E. (1998). Induction of a Th1 immune response and simultaneous lack of activation of a [2Th] response are required for generation of immunity to leishmaniasis. J. Immunol. 160, 3949-3957.
138. Skeen, M. J., Miller, M. A., Shinnick, T. M., and Ziegler, H. K. (1996). Regulation of murine macrophage IL-12 production. Activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines. J. Immunol. 156, 1196-1206.
139. Sosa, M. R., Rosas, L. E., McKenzie, A. N., and Satoskar, A. R. (2001). IL-13 gene-deficient mice are susceptible to cutaneous L. mexicana infection. Eur. J. Immunol. 31, 3255-3260.
140. Spath, G. F., Garraway, L. A., Turco, S. J., and Beverley, S. M. (2003a). The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc. Natl. Acad. Sci. U.S.A. 100, 9536-9541.
141. Spath, G. F., Lye, L. F., Segawa, H., Sacks, D. L., Turco, S. J., and Beverley, S. M. (2003b). Persistence without pathology in phosphoglycandeficient Leishmania major. Science 301, 1241-1243.
142. Spath, G. F., Lye, L.-F., Segawa, H., Turco, S. J., and Beverley Stephen, M. (2004). Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. Infect. Immun. 72, 3622-3627.
143. Suffia, I., Reckling, S. K., Salay, G., and Belkaid, Y. (2005). A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection. J. Immunol. 174, 5444-5455.
144. Suffia, I. J., Reckling, S. K., Piccirillo, C. A., Goldszmid, R. S., and Belkaid, Y. (2006). Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J. Exp. Med. 203, 777-788.
145. Swihart, K., Fruth, U., Messmer, N., Hug, K., Behin, R., Huang, S., Del Giudice, G., Aguet, M., and Louis, J. A. (1995). Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response. J. Exp. Med. 181, 961-971.
146. Tabbara, K. S., Peters, N. C., Afrin, F., Mendez, S., Bertholet, S., Belkaid, Y., and Sacks, D. L. (2005). Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection. Infect. Immun. 73, 4714-4722.
147. Tewary, P., Sukumaran, B., Saxena, S., and Madhubala, R. (2004). Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen. Vaccine 22, 3053-3060.
148. Titus, R. G., Gueiros-Filho, F. J., de Freitas, L. A., and Beverley, S. M. (1995). Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. U.S.A. 92, 10267-10271.
149. Titus, R. G., Sherry, B., and Cerami, A. (1989). Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J. Exp. Med. 170, 2097-2104.
150. Uzonna, J. E., Joyce, K. L., and Scott, P. (2004a). Low dose Leishmania major promotes a transient T helper cell type 2 response that is downregulated by interferon gammaproducing CD8+ T cells. J. Exp. Med. 199, 1559-1566.
151. Uzonna, J. E., Späth, G. F., Beverley, S. M., and Scott, P. (2004b). Vaccination with phosphoglycandeficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol. 172, 3793-3797.
152. Uzonna, J. E., Wei, G., Yurkowski, D., and Bretscher, P. (2001). Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J. Immunol. 167, 6967-6974.
153. van Thiel, P. P., Leenstra, T., de Vries, H. J., van der Sluis, A., van Gool, T., Krull, A. C., van Vugt, M., de Vries, P. J., Zeegelaar, J. E., Bart, A., van der Meide, W. F., Schallig, H. D., Faber, W. R., and Kager, P. A. (2010). Cutaneous leishmaniasis (Leishmania major infection) in Dutch troops deployed in northern Afghanistan: epidemiology, clinical aspects, and treatment. Am. J. Trop. Med. Hyg. 83, 1295-1300.
154. van Zandbergen, G., Bollinger, A., Wenzel, A., Kamhawi, S.,Voll, R., Klinger, M., Müller, A., Hölscher, C., Herrmann, M., Sacks, D., Solbach, W., and Laskay, T. (2006). Leishmania disease development depends on the presence of apoptotic promastigotes in the virulent inoculum. Proc. Natl. Acad. Sci. U.S.A. 103, 13837-13842.
155. van Zandbergen, G., Klinger, M., Mueller, A., Dannenberg, S., Gebert, A., Solbach, W., and Laskay, T. (2004). Cutting edge: neutrophil granulocyte serves as a vector for Leishmania entry into macrophages. J. Immunol. 173, 6521-6525.
156. Vargas-Inchaustegui, D. A., Xin, L., and Soong, L. (2008). Leishmania braziliensis infection induces dendritic cell activation, ISG15 transcription, and the generation of protective immune responses. J. Immunol. 180, 7537-7545.
157. Varkila, K., Chatelain, R., Leal, L. M., and Coffman, R. L. (1993). Reconstitution of C.B-17 scid mice with BALB/c T cells initiates a T helper type-1 response and renders them capable of healing Leishmania major infection. Eur. J. Immunol. 23, 262-268.
158. Velez, I. D., del Pilar Agudelo, S., Arbelaez, M. P., Gilchrist, K., Robledo, S. M., Puerta, J. A., Zicker, F., Berman, J., and Modabber, F. (2000). Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial. Trans. R. Soc. Trop. Med. Hyg. 94, 698-703.
159. Von Stebut, E. (2007). Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity. Eur. J. Dermatol. 17, 115-122.
160. Wang, Z. E., Reiner, S. L., Hatam, F., Heinzel, F. P., Bouvier, J., Turck, C. W., and Locksley, R. M. (1993). Targeted activation of CD8 cells and infection of beta 2-microglobulindeficient mice fail to confirm a primary protective role for CD8 cells in experimental leishmaniasis. J. Immunol. 151, 2077-2086.
161. Wilhelm, P., Ritter, U., Labbow, S., Donhauser, N., Röllinghoff, M., Bogdan, C., and Körner, H. (2001). Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF. J. Immunol. 166, 4012-4019.
162. Wu, C. Y., Wang, K., McDyer, J. F., and Seder, R. A. (1998). Prostaglandin E2 and dexamethasone inhibit IL12 receptor expression and IL-12 responsiveness. J. Immunol. 161, 2723-2730.
163. Wu, W., Huang, L., and Mendez, S. (2010). A live Leishmania major vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL/6 mice. Eur. J. Immunol. 40, 2517-2527.
164. Wu, W., Weigand, L., Belkaid, Y., and Mendez, S. (2006). Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides. Eur. J. Immunol. 36, 3238-3247.
165. Wu, W., Weigand, L., and Mendez, S. (2009). The IL-6-deficient mouse exhibits impaired lymphocytic responses to a vaccine combining live Leishmania major and CpG oligodeoxynucleotides. Can. J. Microbiol. 55, 705-713.
166. Xu, G., Liu, D., Fan, Y., Yang, X., Korner, H., Fu, Y. X., and Uzonna, J. E. (2007a). Lymphotoxin alpha beta 2 (membrane lymphotoxin) is critically important for resistance to Leishmania major infection in mice. J. Immunol. 179, 5358-5366.
167. Xu, G., Liu, D., Okwor, I., Wang, Y., Korner, H., Kung, S. K., Fu, Y. X., and Uzonna, J. E. (2007b). LIGHT is critical for IL-12 production by dendritic cells, optimal CD4+ Th1 cell response, and resistance to Leishmania major. J. Immunol. 179, 6901-6909.
168. Yao, C., Donelson, J. E., and Wilson, M. E. (2003). The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function. Mol. Biochem. Parasitol. 132, 1-16.
169. Yurchenko, E., Tritt, M., Hay, V., Shevach, E. M., Belkaid, Y., and Piccirillo, C. A. (2006). CCR5dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J. Exp. Med. 203, 2451-2460.
170. Zadeh-Vakili, A., Taheri, T., Taslimi, Y., Doustdari, F., Salmanian, A. H., and Rafati, S. (2004). Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis. Vaccine 22, 1930-1940.
171. Zaph,C., Uzonna, J., Beverley,S. M.,and Scott, P. (2004). Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10, 1104-1110.
172. Zhang, L., Yuan, S., Cheng, G., and Guo, B. (2011). Type I IFN promotes IL10 production from T cells to suppress th17 cells and th17-associated autoimmune inflammation. PLoS ONE 6, e28432. doi:10.1371/journal.pone.0028432